SLCO1B1 and myopathy: Limitations of the case report: Muscle biopsy or genetic myopathy testing was not performed, as the patient’s clinical improvement and rapid CK decline following drug discontinuation and hydration supported a toxic-metabolic etiology, making primary myopathy less likely. We acknowledge the absence of statin plasma concentration measurements and pharmacogenetic testing (e.g., SLCO1B1 variants) as study limitations. The synergistic mechanism between empagliflozin and statin toxicity remains hypothesized rather than definitively proven.